Erik Lundgren
multiple sclerosis

Immunic CEO: “We want to understand MS patients better than anyone”

,

Immunic is preparing to transition from a late-stage development biotechnology company into a fully integrated commercial organization focused on multiple sclerosis (MS). At the center of its strategy is vidofludimus calcium, an oral therapy being developed for relapsing and progressive MS. European Biotech spoke with Immunic’s CEO Erik Lundgren about the company’s clinical trials and commercial ambitions, the role of neuroprotection and why he believes the next major opportunity in MS may lie beyond relapse control.

Read more
Ute Kilger
intellectual property

G 1/25: Form over function and how expensive is it?

,

In proceedings before the European Patent Office (EPO), applicants are required to „adapt“ the description to the claims of a patent application once the claims are deemed allowable. The adaptation of the description is an extensive and very costly writing exercise. There was inconsistent case law of the Boards of Appeal (TBoA) on whether and to what extent said adaptation is necessary. The Enlarged Board of Appeal (EBoA) has now decided, and it changes for the worse for the practitioner.

Read more
welcome aboard ship
licensing

AstraZeneca boards the PD-1/VEGF ship with $2B Summit investment

AstraZeneca has agreed to invest $2 billion (€1.8 billion) in Summit Therapeutics and test its cancer drug ivonescimab alongside the British pharma’s antibody-drug conjugates.

Read more
stock falling down
clinical data

uniQure falls as Huntington’s gene therapy shows mixed results

uniQure’s shares fell about 40% in early trading on September 29 after its Huntington’s gene therapy missed statistical significance on the main disease progression measure after four years. The Dutch biotech reported continued slowing of decline with AMT-130, but the update complicates the durability picture as the company seeks regulatory approval.

Read more
heart model plastic
fundraising

AnaCardio raises €62.5M to test heart failure drug

Swedish biotech AnaCardio has raised €62.5 million to take its oral heart failure drug AC01 through Phase 2b, testing whether early improvements in pumping function hold up in a larger patient population.

Read more
money piggybank funding
startups

Aptadir secures €40M for gene-reactivating RNA drugs

Aptadir Therapeutics has raised €40 million in seed funding to advance an RNA therapy designed to reactivate the gene silenced in Fragile X syndrome.

Read more
Photo: Getty Images for Unsplash+
funding

Breye raises €67.5M for diabetic eye disease trial with Novo Holdings backing

Danish biotech Breye Therapeutics has raised €67.5 million to advance an oral eye disease drug candidate into a Phase 2 clinical trial.

Read more
Weight-loss pill
anti-obesity

Novo pays up to $2.6B for Hengrui’s once-weekly obesity pill candidate

Novo Nordisk will pay China’s Jiangsu Hengrui Pharmaceuticals $300 million (€264 million) upfront, in a deal worth up to $2.6 billion (€2.3 billion), for rights outside Greater China to HRS-1596, an experimental obesity and diabetes pill that the companies say could be taken once a week.

Read more
spain map pushpin location
Watchlist

Six Spanish biotech ­startups to watch in 2026

,

The 2025 AseBio Report shows a Spanish biotech ecosystem that is not only expanding, but attracting capital at a new scale: Spain counted 1,119 dedicated biotech companies in 2025, up 10.4% year on year, while 39 new biotech firms were created in 2025.

Read more
stop sign street
Regulatory

FDA keeps Newron’s evenamide trial on hold in U.S.

Newron Pharmaceuticals will expand its Phase 3 evenamide trial outside the U.S. after the FDA decided to maintain a hold on enrollment at American sites.

Read more